Related Experiment Video
Updated: Feb 27, 2026

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model
Published on: April 12, 2024
L-Carnitine Supplementation Improves Self-Rating Depression Scale Scores in Uremic Male Patients Undergoing
Kyoko Tashiro1, Yusuke Kaida2, Sho-Ichi Yamagishi3
1Research Institute of Medical Mass Spectrometry.
Insights
L-carnitine supplementation improved depression in male hemodialysis patients. Low butyryl-carnitine levels predicted a positive response, suggesting its potential as a biomarker for treatment efficacy.
Area of Science:
- Nephrology
- Psychiatry
- Nutritional Science
Background:
- Depression is common in patients undergoing hemodialysis (HD).
- Previous research linked low free-carnitine to depression severity in male HD patients.
- The efficacy of L-carnitine supplementation for depression in this group was uncertain.
Purpose of the Study:
- To investigate the effect of L-carnitine supplementation on depression in male patients undergoing HD.
- To identify carnitine levels that may predict treatment response.
Main Methods:
- Sixteen male HD patients received oral or IV L-carnitine for 3 months.
- Depression was assessed using the Self-Rating Depression Scale (SDS).
- Serum carnitine levels were measured by tandem mass spectrometry at baseline and 3 months.
Main Results:
- L-carnitine supplementation increased serum free and acylcarnitine levels.
- Improved SDS scores correlated with increased carnitine levels.
- Low baseline butyryl-carnitine levels independently predicted reduced SDS scores post-treatment.
Conclusions:
- Three months of L-carnitine supplementation improved depression in male uremic patients on HD.
- Low butyryl-carnitine may predict clinical response to L-carnitine in mild depression among HD patients.
Background:
Depression is highly prevalent in uremic patients undergoing hemodialysis (HD). We previously found that low free-carnitine levels are associated with depression severity in male patients undergoing HD. However, whether L-carnitine supplementation improves the depression state in male patients undergoing HD remains unclear.
Methods:
Sixteen male patients undergoing HD were orally administered 900 mg L-carnitine daily or intravenously administered 1000 mg L-carnitine immediately after undergoing HD for 3 months. The depression state and various types of carnitine levels were evaluated using the self-rating depression scale (SDS) and tandem mass spectrometry, respectively, at baseline and 3 months after treatment.
Results:
L-carnitine supplementation significantly increased serum levels of free and other acylcarnitine types, associated with improved SDS scores in male patients undergoing HD. Univariate analysis revealed that low baseline butyryl- and isovaleryl-/2-methylbutyryl-carnitine levels were significantly correlated with SDS scores after treatment. Multiple regression analysis revealed that butyryl-carnitine levels were a sole independent predictor of SDS scores after treatment (r2 = 0.533).
Conclusion:
L-carnitine supplementation for 3 months improved the depression state in uremic male patients undergoing HD. Thus, low butyryl-carnitine levels may predict the clinical response to L-carnitine supplementation in male patients undergoing HD and who have mild depression.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Hemodialysis III: Nursing Management
Nephrotic Syndrome III : Nursing Management
Peritoneal Dialysis III: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
